HIV+Hep’s Carl Schmid’s presentation before the NAIC Regulatory Framework Task Force on the value of copay assistance for Rx, state laws that ensure copay assistance counts, and ways to mitigate any potential conflicts with those state laws with IRS/Health Savings Account issues.
Details the harmful impacts copay accumulators have on drug adherence and patients costs, federal and state actions taken to date to ensure copay assistance counts, and advocacy opportunities at the federal and state levels patient groups can engage in relative to copay accumulators.
Examines how insurance benefit design, including high deductibles and co-insurance, impact prescription drug access, along with the importance of copay assistance and how states are ensuring that it count towards beneficiary cost-sharing obligations.
Details policies and programs needed to ensure and promote PrEP access to #endHIV: reviewing insurance plans to see if they follow the ACA requirement to cover PrEP w/o patient cost-sharing, the need for greater funding of @CDC_HIVAIDS & community health centers, & potential USPSTF evaluation of long-acting PrEP products
Examines the federal requirement for private insurers to cover PrEP without cost-sharing, state actions to comply, transparency issues, and next steps for enforcing the requirement.